18 F-FDG tissue uptake was measured using the standardized uptake value corrected for the partial volume effect (PVC-SUV) and the total lesion glycolysis (TLG) with (TLG tot+ln ) and without (TLG totÀln ) lymph nodes. Disease activity was assessed by means of clinical parameters [IgG4-RD Responder Index (RI)], serological (ESR and CRP) and immunological (serum IgG4 and circulating plasmablasts) biomarkers. The enhanced liver fibrosis score was exploited as a biomarker for fibroblast activation.
Introduction
IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition characterized by a perturbation of the B cell compartment, which ultimately leads to increased production of IgG4 antibodies, and presumably to fibroblast activation [1] . Definitive diagnosis of IgG4-RD requires the demonstration of specific histological features since available biomarkers, including serum IgG4 levels, have demonstrated relevant shortcomings for diagnostic purposes [2, 3] .
[ 18 F]Fluorodeoxyglucose ( 18 F-FDG) PET/CT has been proposed as an additional tool for the diagnostic workup of IgG4-RD due to the comprehensive overview of organ involvement provided by this imaging technique [46] . As opposed to conventional ultrasonography and CT scanning, 18 F-FDG PET/CT can support the diagnosis of IgG4-RD through the identification of typical localizations and the selection of informative biopsy sites [7, 8] . In addition, 18 F-FDG PET/CT has been increasingly used in the follow-up of patients with IgG4-RD for assessing response to immunosuppressive treatments and for monitoring disease relapse [9, 10] . However, despite its progressive diffusion in the management of patients with IgG4-RD, PET/CT findings are considered bona fide surrogates of IgG4-RD activity because the immunopathological events responsible for 18 F-FDG uptake in IgG4-RD lesions are largely unknown. In order to address the potential correlations between 18 F-FDG PET/CT findings and IgG4-RD activity, we quantified the 18 F-FDG uptake of IgG4-RD lesions using accurate quantitative parameters and correlated them with the following validated clinical, serological and immunological biomarkers of IgG4-RD: IgG4-RD Responder Index (RI) [11] , CRP, ESR, serum IgG4 levels, circulating plasmablasts and the enhanced liver fibrotic (ELF) score. The level of circulating plasmablasts and the ELF score were used as indicators of B cells and fibroblast activation, respectively, two major immunopathological features of IgG4-RD [12, 13, 14] . Circulating plasmablasts, the precursors of tissue resident antibody secreting plasma cells, are also considered the best currently available biomarker of IgG4-RD activity because they are elevated in patients with untreated IgG4-RD, decline with disease remission and re-emerge during disease flare [12] .
Methods

Patients
Twenty consecutive patients with active untreated IgG4-RD referred to our tertiary care centre between June 2012 and June 2016 were included in the present observational prospective cohort study. Patients with exclusive lymph node involvement were excluded given the challenging differentiation between reactive and IgG4-RD lymphadenopathy on PET/CT scan. IgG4-RD was diagnosed according to the 'Consensus statement on the pathology of IgG4-RD'; the 'Comprehensive diagnostic criteria for IgG4-RD' were used when tissue biopsies were not available [2, 15] . Patients with pancreatic involvement who did not undergo pancreatic resection were diagnosed with definite IgG4-RD according to the 'International consensus diagnostic criteria for autoimmune pancreatitis' [16] . IgG4-RD activity was assessed by means of the IgG4-RD RI, a tool developed for clinical trials to define active disease (IgG4-RD RI > 3), disease remission (IgG4-RD RI < 3 off glucocorticoid therapy) and complete response to immunosuppressive treatments (IgG4RD RI < 3 on treatment) [11, 17] . All patients gave written informed consent for the analyses performed. were cross-calibrated with a dose measurement system and optimized to guarantee the comparability of quantitative PET data. PET images were reconstructed including the corrections for random, scatter and attenuation and analysed both qualitatively and quantitatively. Reconstructed PET images were reviewed by two nuclear medicine physicians and by two immunologists expert in IgG4-RD in order to achieve consensus on IgG4-RD organ involvement. Foci of increased glucose metabolism (i.e. IgG4-RD lesions) were segmented by an automatic technique in order to define a discrete metabolic volume (MV) [19] . Quantitative assessment of the radiotracer uptake within a given MV was then evaluated by means of the mean body-weighted standardized uptake value corrected for partial volume effect (PVC-SUV) and the total lesion glycolysis (TLG) [20] . The IgG4-RD lesion with the highest PVC-SUV was selected for correlation studies in patients with multi-organ involvement. Lesions with a sphere-equivalent diameter <1 cm were not considered because of the risk of low quantification accuracy [20] . TLG was calculated for each quantified uptake as the product of mean PVC-SUV and MV by combining volumetric and metabolic information. In order to obtain a surrogate quantitative biomarker of total disease burden, the TLG of each lesion was summed in order to obtain a total TLG for each patient. Total TLG was calculated both excluding (TLG totÀln ) and including (TLG tot+ln ) lymph nodes. The 18 F-FDG-PET/CT scan was repeated in 10 patients to assess disease activity after immunosuppressive treatment.
Statistical analysis
Variables are presented as median and interquartile range for serological and immunological biomarkers and FDG-PET measurements, unless otherwise specified. Prism version 6.00 was utilized for statistical analysis (GraphPad Software, La Jolla, CA, USA). Categorical variables were compared using Fisher's exact test. Normally and non-normally distributed variables were compared using Student's t-test and the MannWhitney U-test, respectively. Parametric correlations were calculated using Spearman's correlation test. P < 0.05 was considered statistically significant.
Results
Clinical, serological and immunological features of the patient cohort at baseline Twenty patients (13 males, 7 females) with a mean age of 61 years (range, 30À78 years) were included in the study (Table 1) . Twelve patients with available histological examination were diagnosed as definite IgG4-RD according to the 'Consensus statement on the pathology of IgG4-RD' [2] and the 'Comprehensive diagnostic criteria for IgG4-RD' [15] . Four patients without available tissue biopsies but with characteristic pancreatic involvement were diagnosed as definite IgG4-RD according to the 'International consensus diagnostic criteria for autoimmune pancreatitis' [16] . One patient with available histology but normal serum IgG4 levels was diagnosed as probable IgG4-RD according to the 'Comprehensive diagnostic criteria for IgG4-RD' [15] . Three patients without available biopsies were diagnosed as possible IgG4-RD according to the 'Comprehensive diagnostic criteria for IgG4-RD' [15] . The aorta and/or its major branches was the most commonly affected organ (seven cases), followed by the pancreas (five cases), lung, orbits, parotid and submandibular glands (three cases each), paranasal sinuses, palate, bone and lacrimal glands (two cases each). The meninges, thyroid and skin were involved in one case each. Thirteen (65%) patients had two or more organs affected by IgG4-RD. All patients had active IgG4-RD as defined by a median IgG4-RD RI value of 9 (range, 6À15; normal <3). The median levels of ESR, CRP, serum IgG4, plasmablasts and ELF score were 19 mm/h (range, 4À121 mm/h, normal <20 mm/h), 4.3 mg/l (range 0.0À48.0 mg/l; normal <6 mg/l), 308 mg/dl (range, 80À2100 mg/dl, normal <135 mg/dl), 2270 cells/ml (range, 130À40 840 cells/ml, normal <650 cells/ml) and 8.9 (range, 7.212.1, normal <7.7), respectively. ESR, CRP, serum IgG4 levels, plasmablasts and ELF score were elevated in 9 (45%), 7 (35%), 17 (85%), 17 (85%) and 11 (55%) patients, respectively. ). IgG4-RD affected organs with the maximum PVC-SUV value were the aorta (six patients), the parotid glands (three patients), the lacrimal glands, the lungs and the pancreas (two patients each), submandibular glands, bone, orbits, meninges and thyroid (one patient each). Eight patients (40%) had evidence of lymph node involvement (Table 1 and Fig. 1 ). The mean PVC-SUV value of the most metabolically active IgG4-RD lesions was 7.63 g/cc (4.81À10.57g/cc). The highest PVC-SUV value was measured in a patient with thyroid involvement. The maximum TLG tot+ln was measured in a patient with aortic and lymph nodes involvement (Table 1 active IgG4-RD lesion and the levels of circulating plasmablasts (r = 0.49, P < 0.05) (Fig. 2) . No statistically significant correlation was found between either TLG tot+ln or TLG totÀln values and IgG4-RD RI, CRP, ESR, serum IgG4 levels and ELF score (P > 0.05 for all the comparisons; supplementary Fig. S2B and C, available at Rheumatology Online). Circulating plasmablasts count did not correlate with TLG tot+ln (P > 0.05) but inversely correlated with TLG totÀln (r = 0.50, P < 0.05; Fig. 2 ).
Quantitative 18 F-FDG PET/CT findings after immunosuppressive therapy
Ten patients underwent a second 18 F-FDG PET/CT scan after a median of 5.5 months (range, 27 months) of immunosuppressive therapy ( Table 2 ). Seven of them were initially treated with oral prednisone (0.51 mg/kg) according to the 'International consensus guidance statement on the treatment of IgG4-RD' [21] ; prednisone was then gradually tapered over a period of 6 months. Two patients were also treated with rituximab (2 i.v. infusions of 1000 mg 15 days apart), and three with oral or s.c. MTX (1520 mg/week). Three patients were treated with MTX alone.
At the time of the second 18 F-FDG PET/CT scan, seven patients were still on glucocorticoids; all of them but patient 3 were on oral prednisone 45 mg/day; patient 3 was on 10 mg/day. Three patients were on MTX alone. All 10 patients were on complete response (i.e. an IgG4-RD RI < 3 on treatment) and showed a consensual reduction of circulating plasmablasts, PVC-SUV, TLG tot+ln and TLG totÀln (Table 2 and Fig. 3 ). The median value of circulating plasmablasts dropped from 2270 cells/ml (range, 13040840 cells/ml) at baseline to 300 cells/ml (range, 03610 cells/ml). The median PVC-SUV calculated on the same IgG4-RD lesions considered for pre-treatment analyses decreased from 7.69 g/cc (4.299.88 g/cc) at baseline to 0 g/cc (05.98 g/cc) (P < 0.05). The median TLG tot+ln , and TLG totÀln values decreased from 351.13 g (153.52506.62 g) and 210.86 g (123.64373.10 g) at baseline to 23.96 g (0240.57 g) (P < 0.05) and 23.96 g (067.27 g) (P < 0.05), respectively. The mean percentage reduction of PVC-SUV, TLG tot+ln and TLG totÀln values compared with baseline was 63 ± 50%, 75 ± 37% and 77 ± 28%, respectively (Fig. 2) . Despite the decrease of circulating plasmablast counts and TLG values after immunosuppressive treatment, PVC-SUV values of the lacrimal gland in patient 3 and of a lung lesion in patient 12 increased from 10.91 to 13.45 g/cc and from 8.31 to 10.74 g/cc, respectively (Fig. 3) . TLG values in patient 5 increased from 528.54 to 621.21 g when lymph nodes were included in the measurement (TLG tot+ln ), and decreased from 165.70 to 115.02 g when lymph nodes were excluded (TLG totÀln ) ( Table 2 and Fig. 3 ). A major novelty of our study is represented by the assessment of IgG4-RD activity using two quantitative 18 F-FDG PET/CT biomarkers: PVC-SUV and TLG. As opposed to other PET/CT biomarkers adopted in previous studies such as SUV max and SUV mean [7, 9] , SUV and TLG with partial volume correction offer more reliable metabolic information and more accurate quantification of 18 F-FDG uptake because they are less influenced by the dimension of the target lesion. This bias is known as the partial volume effect and is thought to underestimate up to 80% of the real 18 F-FDG uptake [1924] . In the present work we correlate validated clinical and serological biomarkers of IgG4-RD activity with quantitative 18 F-FDG PET/CT parameters, and demonstrate that 18 F-FDG uptake of IgG4-RD lesions likely reflects immunological perturbations of the B cell compartment rather than processes related to fibroblast activation and extracellular matrix deposition. In particular, we show that the levels of circulating plasmablasts positively correlate with PVC-SUV suggesting that of TLG values. Similar clinicalradiological discrepancies are frequently encountered in oncological settings, and occur when both metabolic and volumetric PET/CT parameters of neoplastic lesions are not modified accordingly in response to chemotherapy [25] . This was indeed a major concern while assessing IgG4-RD activity on PET/CT scan after treatment. In particular, common confounding scenarios stemmed from the appearance of novel lymph nodes with high 18 F-FDG uptake, typically in the mediastinum or abdomen; increased or persistent 18 F-FDG uptake in pre-existing lymph nodes; increased or persistent 18 F-FDG uptake in organs showing dimensional improvement; and decreased 18 F-FDG uptake in organs showing volumetric increase. In addition, TLG values showed different responses to treatment depending on whether lymph nodes were included in the measurement ( [12] . Second, we show that these quantitative PET/CT parameters can be used for longitudinally following the response to immunosuppression. Third, we describe how volumetric and metabolic responses of IgG4-RD lesions in the same patient might differ after immunosuppressive treatment, thus complicating the interpretation of residual disease activity in the case of multiple organ involvement. Finally, our results indicate that lymph nodes represent a confounding variable in the assessment of the overall IgG4-RD burden since PET/CT studies cannot discriminate between reactive and IgG4-RD lymph nodes. A close collaboration between clinicians and nuclear medicine specialists is, therefore, necessary to interpret 18 F-FDG PET/CT findings in IgG4-RD patients and to avoid over-or underestimation of IgG4-RD burden.
Other routinely used IgG4-RD biomarkers such as serum IgG4 and IgG4-RD RI did not correlate with 18 F-FDG uptake of IgG4-RD lesions, further confirming the shortcomings of both parameters for the assessment of IgG4-RD activity [3, 16] . Indeed, the current IgG4-RD RI algorithm strictly depends on the value of serum IgG4, a biomarker of poor accuracy by itself [11] . Eventually, we did not find any correlation between 18 F-FDG uptake and the ELF score, a recently validated biomarker of systemic fibrosis [13] , suggesting that PET/CT may not be an ideal imaging technique for obtaining clues about fibroblast activation and processes related to collagen deposition.
These results are supported by a number of significant strengths. First, this is a monocentric prospective study designed to correlate IgG4-RD activity with the most accurate biomarkers of 18 F-FDG uptake. In addition, our study cohort is derived from one of the largest single centre cohorts of IgG4-RD patients, an aspect that ensured uniform inclusion criteria and follow-up [26] . Furthermore, 18 F-FDG PET/CT data were obtained on cross-calibrated PET/CT scanners, thus allowing more reliable comparisons between patients, before and after treatment. Our work has also some limitations. Despite a thorough quantitative analysis, in fact, the FDG-PET/CT scan is inherently unable to differentiate reactive from pathological lymph nodes and, thus, to unequivocally define IgG4-RD burden, especially in patients with multi-organ involvement. In addition, although our results correlate circulating plasmablasts and 18 F-FDG uptake in IgG4-RD lesions, a full comprehension of the immunopathological events sustaining PET/CT findings in this condition would require further correlation studies between imaging and pathological features. Finally, we recognize that more robust information could have been obtained from a larger cohort of patients; however, we decided to limit our analysis to 20 subjects who had laboratory tests and PET/CT scan performed on the same day in order to extrapolate more reliable correlations.
In conclusion, we present the first systematic analysis of the relationship between PET/CT scan findings and IgG4-RD activity by correlating quantitative biomarkers of 18 F-FDG uptake and IgG4-RD. Thanks to this systematic approach we have unveiled the immunological basis for considering PET/CT a reliable instrument for assessing IgG4-RD activity. In addition, the evidence that PET/CT parameters reflect perturbations of the B cell compartment provides a solid rationale for further studies aiming to understand whether 18 F-FDG PET/CT can be used to predict response to B cell depletion therapy. Disclosure statement: The authors have declared no conflicts of interest.
